Insmed Incorporated (INSM) FY2025 10-K Annual Report
Insmed Incorporated (INSM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Insmed Incorporated FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of specialty pharmaceuticals focusing on respiratory diseases, including key marketed products ARIKAYCE and BRINSUPRI
- • New product emphasis: BRINSUPRI launch in August 2025 generated $172.7M US sales in 2025, contributing to 66.7% overall revenue growth to $606.4M
- • Strategic shift: Accelerated commercial readiness and significant investment in BRINSUPRI’s US launch, plus acquisition of INS1148 for $40M in 2025, expanding pipeline
- • Notable quantitative metrics: R&D expenses rose 28.9% to $771.1M, SG&A increased 52.1% to $701.2M, driven by headcount growth and commercial activities for BRINSUPRI
- • Unique fact: Completed two large equity offerings in 2024 and 2025, raising net proceeds of $713.2M and $823.3M respectively, bolstering cash reserves to support operations
Management Discussion & Analysis
- • Revenue not disclosed in provided text, no YoY change available
- • Profitability or margin details not provided in the excerpt
- • Respiratory therapeutic area is the only commercial segment with two approved products: ARIKAYCE and BRINSUPRI
- • No cash flow, buybacks, dividends, or capex details mentioned
- • Forward-looking: portfolio focused on Respiratory, Inflammation & Immunology, Neuro & Rare diseases, with ongoing clinical and pre-clinical programs spanning advanced modalities
Risk Factors
- • FDA accelerated approval of ARIKAYCE contingent on successful ENCORE confirmatory trial with 425 patients enrolled as of Q4 2024
- • Exposure to inflation affecting suppliers, service providers, and partners across US, Europe, Japan, and global operations
- • Dependence on Lamira device regulatory approval in each market for ARIKAYCE commercialization limits product sales capability
- • Competitive market risks amid reliance on market acceptance against alternatives amid safety concerns like US boxed warning on ARIKAYCE
- • Outstanding term loan and royalty financing arrangement may limit financial flexibility and increase risk of shareholder dilution
Insmed Incorporated FY2025 Key Financial MetricsXBRL
Revenue
$606M
▲ +66.7% YoY
Net Income
-$1.3B
▼ -39.7% YoY
Operating Margin
-205.6%
▲ +3588bp YoY
Net Margin
-210.5%
▲ +4070bp YoY
ROE
-172.8%
▲ +14742bp YoY
Total Assets
$2.3B
▲ +11.8% YoY
EPS (Diluted)
$-6.42
▼ -15.3% YoY
Operating Cash Flow
-$935M
▼ -36.7% YoY
Source: XBRL data from Insmed Incorporated FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Insmed Incorporated
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.